• How does variability in data preprocessing pipelines impact the reliability of structure based and ligand based modelling outcomes • Which preprocessing steps introduce the greatest uncertainty into drug design models, and why • How are teams assessing the downstream impact of preprocessing choices on model performance and decision making • What level of standardization is realistic without limiting methodological innovation in drug design workflows • How can modelling teams better communicate preprocessing assumptions and uncertainty to project stakeholders